Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma

Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored. Using highly-sensitive Proximity Extension ImmunoAssay on 92 cancer biomarkers (Proseek Multiplex, Olink), enhanced serum levels of Adrenome...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Oncotarget Ročník 8; číslo 41; s. 69408
Hlavní autori: Schneiderova, Petra, Pika, Tomas, Gajdos, Petr, Fillerova, Regina, Kromer, Pavel, Kudelka, Milos, Minarik, Jiri, Papajik, Tomas, Scudla, Vlastimil, Kriegova, Eva
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 19.09.2017
Predmet:
ISSN:1949-2553, 1949-2553
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored. Using highly-sensitive Proximity Extension ImmunoAssay on 92 cancer biomarkers (Proseek Multiplex, Olink), enhanced serum levels of Adrenomedullin (ADM, = .0004), Growth differentiation factor 15 (GDF15, = .003), and soluble Major histocompatibility complex class I-related chain A (sMICA, = .023), all prosurvival and chemoprotective factors for myeloma cells, were detected in MM comparing to MGUS. Comparison of MGUS and healthy subjects revealed elevation of angiogenic and antia-poptotic midkine ( = .0007) and downregulation of Transforming growth factor beta 1 (TGFB1, = .005) in MGUS. Importantly, altered serum pattern was associated with MM-ASCT compared to paired MM at the diagnosis as well as to healthy controls, namely by upregulated B-Cell Activating Factor (sBAFF) ( < .006) and sustained elevation of other pro-tumorigenic factors. In conclusion, the serum fingerprints of MM and MM-ASCT were characteristic by elevated levels of prosurvival and chemoprotective factors for myeloma cells.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.11242